Skip to main content
BALAXI PHARMACEUTICALS LIMITED logo

BALAXI PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · BALAXI ISIN · INE618N01022 LEI · 894500VRENAYIIWHHQ13 National Stock Exchange of India Wholesale and retail trade
Open in API
Filings indexed 615 across all filing types
Latest filing 2025-05-30 Capital/Financing Update
Country IN India
Listing National Stock Exchange of India BALAXI

About BALAXI PHARMACEUTICALS LIMITED

https://www.balaxipharma.in/

Balaxi Pharmaceuticals Limited is a specialty pharmaceutical company that operates an asset-light business model focused on sourcing, branding, and distributing generic formulations in frontier markets. The company primarily serves emerging economies across Africa and Latin America, including Angola, Guatemala, and the Dominican Republic. Its product portfolio encompasses a wide range of therapeutic segments such as anti-infectives, analgesics, and antimalarials. Balaxi manages an integrated supply chain, leveraging its regulatory expertise to register and market high-quality pharmaceutical products. By maintaining a robust distribution network and localized presence, the company ensures the availability of essential medicines in underserved regions while optimizing operational efficiency through its specialized procurement and logistics framework.

Recent filings

Filing Released Lang Actions
Statement of deviation(s) or variation(s) under Reg. 32
Capital/Financing Update Classification · 95% confidence The document is a statement regarding the deviation or variation in the utilization of funds raised through a preferential issue for the quarter ended March 31, 2025. It references SEBI regulations and provides detailed information about the mode of fund raising, dates, amounts raised, and confirms no deviation in fund usage. This type of document is a regulatory compliance disclosure related to capital raising activities, specifically about fund utilization deviations. It is not a full financial report, audit report, or earnings release. It is also not a report publication announcement since it contains substantive information rather than just announcing a report. The document fits best under Capital/Financing Update (CAP) as it updates on the use of funds raised through financing activities.
2025-05-30 English
Integrated Filing- Financial
Annual Report Classification · 95% confidence The document is a detailed announcement of the outcome of a Board Meeting held on May 30, 2025, by Balaxi Pharmaceuticals Limited. It includes approval of standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2025, accompanied by the audit report. It also mentions re-appointment of auditors and appointment of secretarial auditors, updates on a pharmaceutical plant, and approval of the AGM notice. The document contains actual financial data tables for the quarter and year ended March 31, 2025, including income, expenses, profit/loss, and earnings per share. The presence of comprehensive audited financial results and audit report details within the document itself indicates this is the official Annual Report or equivalent full-year financial report. It is not merely an announcement or a brief summary but contains substantive financial data and audit information. Therefore, the correct classification is Annual Report (10-K).
2025-05-30 English
General Updates
Annual Report Classification · 95% confidence The document is a detailed announcement from the Board of Directors of Balaxi Pharmaceuticals Limited regarding the outcome of their board meeting held on May 30, 2025. It includes approval of standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2025, accompanied by the audit report from statutory auditors. It also mentions re-appointment of internal auditors and appointment of secretarial auditors, updates on a pharmaceutical plant, and approval of the AGM notice. The document contains actual financial data including income, expenses, profit/loss, and EPS figures for the relevant periods. The presence of audited financial results and audit report details indicates this is a comprehensive financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Annual Report (10-K) type filing, as it covers full financial performance for the fiscal year and includes audit information. Confidence is high given the detailed financial tables and audit references.
2025-05-30 English
General Updates
Audit Report / Information Classification · 95% confidence The document is a detailed announcement from the Board of Directors of Balaxi Pharmaceuticals Limited regarding the outcome of their board meeting held on May 30, 2025. It includes approval of standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2025, accompanied by the audit report. The document also mentions re-appointment of auditors and appointment of secretarial auditors, updates on a pharmaceutical plant, and approval of the AGM notice. The presence of detailed audited financial results and audit report indicates this is a financial results announcement with audit information. However, the document is primarily an announcement of the audited financial results and audit report approval rather than the full annual report itself. Given the detailed financial data and audit report inclusion, this fits best under Audit Report / Information (AR) rather than Annual Report (10-K) or Earnings Release (ER). The document length (15,000 characters) and content confirm it is not a brief announcement or a certification letter, so it is not RNS or RPA. Therefore, the classification is AR with high confidence.
2025-05-30 English
Outcome of Board Meeting
Annual Report Classification · 95% confidence The document is a detailed announcement from the Board of Directors of Balaxi Pharmaceuticals Limited dated May 30, 2025. It includes the approval of standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2025, accompanied by the audit report from statutory auditors. The document also mentions re-appointment of internal and secretarial auditors, updates on a pharmaceutical plant, and approval of the AGM notice. The financial results tables contain detailed financial data for the quarter and year ended March 31, 2025. The document is comprehensive and contains substantive financial data and analysis, not just an announcement or summary. Therefore, it is a full financial report for the fiscal year, consistent with an Annual Report filing. It is not merely an announcement of results (which would be ER), nor a short notice or certification (RNS). Hence, the appropriate classification is Annual Report (10-K).
2025-05-30 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-05-21 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.